Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Romero Aroca, Pedro ^a   Baget Bernaldiz, Marc ^a   Pareja Rios, Alicia ^b   Lopez Galvez, Maribel ^c   Navarro Gil, Raul ^a   Verges, Raquel ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOGENESIS INHIBITOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; DEXAMETHASONE; GLUTAMIC ACID; INTERCELLULAR ADHESION MOLECULE 1; PROTEIN KINASE C; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; BIOMICROSCOPY; BLOOD RETINA BARRIER; CYTOTOXICITY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; EDEMA; FLUORESCENCE ANGIOGRAPHY; GENE OVEREXPRESSION; HUMAN; HYPERGLYCEMIA; INFLAMMATION; MUELLER CELL; MULTICENTER STUDY (TOPIC); OPTICAL COHERENCE TOMOGRAPHY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VASOGENIC EDEMA; DIABETES MELLITUS; IMMUNOLOGY; MACULAR EDEMA; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; RETINA;

DIABETES MELLITUS; DIABETIC RETINOPATHY; HUMANS; INFLAMMATION; MACULAR EDEMA; NEOVASCULARIZATION, PATHOLOGIC; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84991650772     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/2156273     Document Type: Review

References (85)

1. International Diabetes Federation, IDF Diabetes Atlas, International Diabetes Federation, Brussels, Belgium, 6th edition, 2013, http://www. idf. org/diabetesatlas.
2. R. R. A. Bourne, G. A. Stevens, R. A. White et al., "Causes of vision loss worldwide, 1990-2010: A systematic analysis, " The Lancet Global Health, vol. 1, no. 6, pp. e339-e349, 2013.
3. P. Romero-Aroca, S. De La Riva-Fernandez, A. Valls-Mateu, R. Sagarra-Alamo, A. Moreno-Ribas, and N. Soler, "Changes observed in diabetic retinopathy: eight-year follow-up of a Spanish population, " British Journal of Ophthalmology, vol. 100, no. 10, pp. 1366-1371, 2016.
4. P. Romero-Aroca, "Targeting the pathophysiology of diabetic macular edema, " Diabetes Care, vol. 33, no. 11, pp. 2484-2485, 2010.
5. Diabetic Retinopathy Guidelines, "The Royal College of Ophthalmologists, " December 2012, https://www. rcophth. Ac. uk/.
6. J. A. Wells, A. R. Glassman, A. R. Ayala et al., "Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema, " The New England Journal of Medicine, vol. 372, pp. 1193-1203, 2015.
7. G. Staurenghi, S. Sadda, U. Chakravarthy, and R. F. Spaide, "International Nomenclature for Optical Coherence Tomography (INoCT) Panel. Proposed lexicon for anatomic land Marks in normal posterior segment spectral-domain optical coherence tomography: The INoCT consensus, " Ophthalmology, vol. 121, no. 8, pp. 1572-1578, 2014.
8. J. Cunha-Vaz, R. Bernardes, and C. Lobo, "Blood-retinal barrier, " European Journal of Ophthalmology, vol. 21, supplement 6, pp. S3-S9, 2011.
9. L. J. Rizzolo, S. Peng, Y. Luo, and W. Xiao, "Integration of tight junctions and claudins with the barrier functions of the retinal pigment epithelium, " Progress in Retinal and Eye Research, vol. 30, no. 5, pp. 296-323, 2011.
10. I. Klaassen, C. J. F. Van Noorden, and R. O. Schlingemann, "Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions, " Progress in Retinal and Eye Research, vol. 34, pp. 19-48, 2013.
11. Y. Zhang and B. R. Bhavnani, "Glutamate-induced apoptosis in neuronal cells is mediated via caspase-dependent and independentmechanisms involving calpain and caspase-3 proteases as well as Apoptosis Inducing Factor (AIF) and this process is inhibited by equine estrogens, " BMC Neuroscience, vol. 7, article 49, 2006.
12. L. P. Aiello and DCCT/EDIC Research Group, "Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study, " Diabetes Care, vol. 37, no. 1, pp. 17-23, 2014.
13. E. M. Kohner, "Microvascular disease: what does the UKPDS tell us about diabetic retinopathy?" Diabetic Medicine, vol. 25, supplement 2, pp. 20-24, 2008.
14. C. M. Warboys and P. A. Fraser, "Hyperglycemia attenuates acute permeability response to advanced glycation end products in retinal microvasculature, " Microvascular Research, vol. 80, no. 1, pp. 174-176, 2010.
15. F. Ismail-Beigi, T. Craven, M. A. Banerji et al., "Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial, " The Lancet, vol. 376, no. 9739, pp. 419-430, 2010.
16. Y. Ono, S. Aoki, K. Ohnishi, T. Yasuda, K. Kawano, and Y. Tsukada, "Increased serum levels of advanced glycation endproducts and diabetic complications, " Diabetes Research and Clinical Practice, vol. 41, no. 2, pp. 131-137, 1998.
17. M. Dai, X.-B. Xia, and S.-Q. Xiong, "BDNF regulates GLAST and glutamine synthetase inmouse retinalMüller cells, " Journal of Cellular Physiology, vol. 227, no. 2, pp. 596-603, 2012.
18. T. Behl, I. Kaur, and A. Kotwani, "Implication of oxidative stress in progression of diabetic retinopathy, " Survey of Ophthalmology, vol. 61, no. 2, pp. 187-196, 2016.
19. Y. Li, F. Zhang, N. Nagai et al., "VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats, " The Journal of Clinical Investigation, vol. 118, no. 3, pp. 913-923, 2008.
20. K. Miyamoto, S. Khosrof, S.-E. Bursell et al., "Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1), " American Journal of Pathology, vol. 156, no. 5, pp. 1733-1739, 2000.
21. A. Vermes, E. Steinmetz, L. Zeyen, and E. Van der Veen, "White blood cells are rheological properties in patients with diabetic microvascular complications, " Diabetologia, vol. 30, no. 6, pp. 434-436, 1987.
22. K. Miyamoto, N. Hiroshiba, A. Tsujikawa, and Y. Ogura, "In vivo demonstration of retinal microcirculation in entrapment leukocyte increased in diabetic rats, " Investigative Ophthalmology & Visual Science, vol. 39, no. 11, pp. 2190-2194, 1998.
23. H. Funatsu, H. Yamashita, S. Nakamura et al., "Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema, " Ophthalmology, vol. 113, no. 2, pp. 294-301, 2006.
24. E. A. Pierce, R. L. Avery, E. D. Foley, L. P. Aiello, and L. E. H. Smith, "Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization, " Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 3, pp. 905-909, 1995.
25. D. W. Dawson, O. V. Volpert, P. Gillis et al., "Pigment epithelium-derived factor: A potent inhibitor of angiogenesis, " Science, vol. 285, no. 5425, pp. 245-248, 1999.
26. G. Gao, Y. Li, D. Zhang, S. Gee, and C. Crosson, "Unbalanced Expression of VEGF induced retinal ischemia and neovascularization in PDF, " FEBS Letters, vol. 489, pp. 270-276, 2001.
27. O. Arjamaa and M. Nikinmaa, "Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors, " Experimental Eye Research, vol. 83, no. 3, pp. 473-483, 2006.
28. X. Wang, G. Wang, and Y. Wang, "Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy, " American Journal of Ophthalmology, vol. 148, no. 6, pp. 883-889, 2009.
29. H. Funatsu, H. Yamashita, K. Sakata et al., "Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema, " Ophthalmology, vol. 112, no. 5, pp. 806-816, 2005.
30. J. Cunha-Vaz, "Diabetic macular edema, " European Journal of Ophthalmology, vol. 8, no. 3, pp. 127-130, 1998.
31. M. A. Bearse Jr., Y. Han, M. E. Schneck, and A. J. Adams, "Retinal function in normal and diabetic eyes mapped with the slow flash multifocal electroretinogram, " Investigative Ophthalmology & Visual Science, vol. 45, no. 1, pp. 296-304, 2004.
32. P.-H. Peng, H.-S. Lin, and S. Lin, "Nerve fibre layer thinning in patients with preclinical retinopathy, " Canadian Journal of Ophthalmology, vol. 44, no. 4, pp. 417-422, 2009.
33. E. L. Fletcher, J. A. Phipps, M. M. Ward, T. Puthussery, and J. L. Wilkinson-Berka, "Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy, " Current Pharmaceutical Design, vol. 13, no. 26, pp. 2699-2712, 2007.
34. S. Mohr, A. Xi, J. Tang, and T. S. Kern, "Caspase activation in retinas of diabetic and galactosemic mice and diabetic patients, " Diabetes, vol. 51, no. 4, pp. 1172-1179, 2002.
35. Y. Feng, Y. Wang, L. Li et al., "Gene expression profiling of vasoregression in the retina-involvement of microglial cells, " PLoS ONE, vol. 6, no. 2, Article ID e16865, 2011.
36. H. Kettenmann, U.-K. Hanisch, M. Noda, and A. Verkhratsky, "Physiology of microglia, " Physiological Reviews, vol. 91, no. 2, pp. 461-553, 2011.
37. K. Saijo and C. K. Glass, "Microglial cell origin and phenotypes in health and disease, " Nature Reviews Immunology, vol. 11, no. 11, pp. 775-787, 2011.
38. M. B. Graeber, W. Li, and M. L. Rodriguez, "Role of microglia in CNS inflammation, " FEBS Letters, vol. 585, no. 23, pp. 3798-3805, 2011.
39. S. Omri, F. Behar-Cohen, Y. De Kozak et al., "Microglia/ macrophages migrate through retinal epithelium barrier by a transcellular route in diabetic retinopathy: role of PKC in the Goto Kakizaki rat model, " American Journal of Pathology, vol. 179, no. 2, pp. 942-953, 2011.
40. E. Ambrosini and F. Aloisi, "Chemokines and glial cells: A complex network in the central nervous system, " Neurochemical Research, vol. 29, no. 5, pp. 1017-1038, 2004.
41. S. Vujosevic, A. Micera, S. Bini, M. Berton, G. Esposito, and E. Midena, "Proteome analysis of retinal glia cells-related inflammatory cytokines in the aqueous humour of diabetic patients, " Acta Ophthalmologica, vol. 94, no. 1, pp. 56-64, 2016.
42. P. J. Khandelwal, A. M. Herman, and C. E.-H. Moussa, "Inflammation in the early stages of neurodegenerative pathology, " Journal of Neuroimmunology, vol. 238, no. 1-2, pp. 1-11, 2011.
43. P. A. Campochiaro, "Ocular neovascularization, " Journal of Molecular Medicine, vol. 91, no. 3, pp. 311-321, 2013.
44. M. W. Stewart, "The expanding role of vascular endothelial growth factor inhibitors in ophthalmology, " Mayo Clinic Proceedings, vol. 87, no. 1, pp. 77-88, 2012.
45. P. Massin, F. Bandello, J. G. Garweg et al., "Safety and efficacy of ranibizumab in diabeticmacular edema (RESOLVE study): A 12-month, randomized, controlled, double-masked, multicenter phase II study, " Diabetes Care, vol. 33, no. 11, pp. 2399-2405, 2010.
46. P. Mitchell, F. Bandello, U. Schmidt-Erfurth et al., "The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema, " Ophthalmology, vol. 118, no. 4, pp. 615-625, 2011.
47. U. Schmidt-Erfurth, G. E. Lang, F. G. Holz et al., "Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: The RESTORE extension study, " Ophthalmology, vol. 121, no. 5, pp. 1045-1053, 2014.
48. M. J. Elman, L. P. Aiello, R. W. Beck et al., "Randomized trial evaluating ranibizumab and prompt or deferred laser or triamcinolone and prompt laser for diabetic macular edema, " Ophthalmology, vol. 117, no. 6, pp. 1064-1077, 2010.
49. M. J. Elman, N. M. Bressler, H. Qin et al., "Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema, " Ophthalmology, vol. 118, no. 4, pp. 609-614, 2011.
50. R. K. Maturi, L. Bleau, J. Saunders, M. Mubasher, and M. W. Stewart, "A 12-Month, Single-Masked, Randomized Controlled Study of eyes with persistent diabetic macular edema after multiple anti-vegf injections to assess the efficacy of the dexamethasone-delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy, " Retina, vol. 35, no. 8, pp. 1604-1614, 2015.
51. M. DutraMedeiros, M. Postorino, R. Navarro, J. Garcia-Arumí, C. Mateo, and B. Corcóstegui, "Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema, " Ophthalmologica, vol. 231, no. 3, pp. 141-146, 2014.
52. Y. Yang, C. Bailey, F. G. Holz et al., "Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants, " Eye, vol. 29, pp. 1173-1180, 2015.
53. P. A. Pearson, T. L. Comstock, M. Ip et al., "Fluocinolone acetonide intravitreal implant for diabetic macular edema: A 3-year multicenter, randomized, controlled clinical trial, " Ophthalmology, vol. 118, no. 8, pp. 1580-1587, 2011.
54. Q. D. Nguyen, D. M. Brown, D. M. Marcus et al., "Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE, " Ophthalmology, vol. 119, no. 4, pp. 789-801, 2012.
55. C. C. Wykoff, M. J. Elman, C. D. Regillo, B. Ding, N. Lu, and I. Stoilov, "Predictors of diabetic macular edema treatment frequency with ranibizumab during the open-label extension of the RIDE and RISE trials, " Ophthalmology, vol. 123, no. 8, pp. 1716-1721, 2016.
56. D. V. Do, Q. D. Nguyen, R. Vitti et al., "Intravitreal aflibercept injection in diabetic macular edema patients with and without prior anti-vascular endothelial growth factor treatment, " Ophthalmology, vol. 123, no. 4, pp. 850-857, 2016.
57. Diabetic Retinopathy Clinical Research Network, J. A. Wells, A. R. Glassman et al., "Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema, " The New England Journal of Medicine, vol. 372, no. 13, pp. 1193-1203, 2015.
58. J. A. Wells, A. R. Glassman, A. R. Ayala et al., "Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial, " Ophthalmology, vol. 123, no. 6, pp. 1351-1359, 2016.
59. D. Grover, T. J. Li, and C. C. Chong, "Intravitreal steroids for macular edema in diabetes, " Cochrane Database of Systematic Reviews, no. 1, Article ID CD005656, 2008.
60. S. H. Byeon, Y. K. Chu, Y. T. Hong, M. Kim, H. M. Kang, and O. W. Kwon, "New insights into the pathoanatomy of diabetic macular edema: Angiographic patterns and optical coherence tomography, " Retina, vol. 32, no. 6, pp. 1087-1099, 2012.
61. T. Otani, S. Kishi, and Y. Maruyama, "Patterns of diabetic macular edema with optical coherence tomography, " American Journal of Ophthalmology, vol. 127, no. 6, pp. 688-693, 1999.
62. S. Vujosevic, M. Varano, C. Egan et al., "Relevance of retinal thickness changes in the OCT inner and outer rings to predict progression to clinical macular edema: An attempt of composite grading of macular edema, " Ophthalmic Research, vol. 55, no. 1, pp. 19-25, 2015.
63. M. Baget-Bernaldiz, Resposta electroretinogràfica obtinguda en pacients diabètics tipus 2 amb edema macular difús tractats amb ranibizumab [Ph. D. Thesis], University Rovira & Virgili, Tarragona, Spain, 2014.
64. S. Vujosevic, M. Berton, S. Bini, M. Casciano, F. Cavarzeran, and E. Midena, "Hyperreflective retinal spots and visual function after anti-vascular endothelial growth factor treatment in center-involving diabetic macular edema, " Retina, vol. 36, no. 7, pp. 1298-1308, 2016.
65. G. Coscas, F. Coscas, S. Vismara, A. Zourdani, and C. I. Li Calzi, "Clinical features and natural history of AMD, " in Optical Coherence Tomography in Age-Related Macular Degeneration, G. Coscas, F. Coscas, S. Vismara, A. Zourdani, and C. I. Li Calzi, Eds., pp. 171-194, Springer, Heidelberg, Germany, 2009.
66. G. Coscas, U. De Benedetto, F. Coscas et al., "Hyperreflective dots: A new spectral-domain optical coherence tomography entity for follow-up and prognosis in exudative age-related macular degeneration, " Ophthalmologica, vol. 229, no. 1, pp. 32-37, 2012.
67. M. Bolz, U. Schmidt-Erfurth, G. Deak et al., "Diabetic Retinopathy Research Group Vienna Optical coherence tomographic hyperreflective foci: A morphologic sign of lipid extravasation in diabetic macular edema, " Ophthalmology, vol. 116, pp. 914-920, 2009.
68. A. Uji, T. Murakami, K. Nishijima et al., "Association between hyperreflective foci in the outer retina, status of photoreceptor layer, and visual acuity in diabetic macular edema, " American Journal of Ophthalmology, vol. 153, no. 4, pp. 710-717. e1, 2012.
69. C. Framme, P. Schweizer, M. Imesch, S. Wolf, and U. Wolf-Schnurrbusch, "Behavior of SD-OCT-detected hyperreflective foci in the retina of anti-VEGF-treated patients with diabetic macular edema, " Investigative Ophthalmology & Visual Science, vol. 53, no. 9, pp. 5814-5818, 2012.
70. S. Vujosevic, M. Berton, S. Bini, M. Casciano, F. Cavarzeran, and E. Midena, "Hyperreflective retinal spots and visual function after anti-vascular endothelial growth factor treatment in center-involving diabetic macular edema, " Retina, vol. 36, no. 7, pp. 1298-1308, 2016.
71. S. Vujosevic and E. Midena, "Retinal layers changes in human preclinical and early clinical diabetic retinopathy support early retinal neuronal and Müller cells alterations, " Journal ofDiabetes Research, vol. 2013, Article ID 905058, 8 pages, 2013.
72. H.-Y. Zeng, W. R. Green, and M. O. M. Tso, "Microglial activation in human diabetic retinopathy, " Archives of Ophthalmology, vol. 126, no. 2, pp. 227-232, 2008.
73. X. Chen, H. Zhou, Y. Gong, S. Wei, and M. Zhang, "Early spatiotemporal characterization of microglial activation in the retinas of rats with streptozotocin-induced diabetes, " Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 253, no. 4, pp. 519-525, 2015.
74. J.-W. Kang, H. Chung, and H. C. Kim, "Correlation of optical coherence tomographic hyperreflective foci with visual outcomes in different patterns of diabetic macular edema, " Retina, vol. 36, no. 9, pp. 1630-1639, 2016.
75. D. Gaucher, C. Sebah, A. Erginay et al., "Optical coherence tomography features during the evolution of serous retinal detachment in patients with diabetic macular edema, "American Journal of Ophthalmology, vol. 145, no. 2, pp. 289-296. e1, 2008.
76. G. G. Deák, M. Bolz, M. Ritter, S. Prager, T. Benesch, and U. Schmidt-Erfurth, "A systematic correlation between morphology and functional alterations in diabetic macular edema, " Investigative Ophthalmology & Visual Science, vol. 51, no. 12, pp. 6710-6714, 2010.
77. H. Gungel and C. Altan, "The relationship between fundus fluorescein angiographic findings and serousmacular detachment in diabetic macular edema, " Retina, vol. 33, no. 9, pp. 1895-1901, 2013.
78. D. Shukla, U. C. Behera, S. Chakraborty, R. Mahalakshmi, and N. M. Prasad, "Serous macular detachment as a predictor of resolution of macular edema with intravitreal triamcinolone injection, " Ophthalmic Surgery Lasers and Imaging, vol. 40, no. 2, pp. 115-119, 2009.
79. H. R. Novonty andD. L. Alvis, "A method of photographing fluorescein in circulating blood in the human retina, " Circulation, pp. 24-82, 1961.
80. M. R. K. Mookiah, U. R. Acharya, H. Fujita et al., "Application of different imaging modalities for diagnosis of Diabetic Macular Edema: A review, " Computers in Biology and Medicine, vol. 66, pp. 295-315, 2015.
81. E. D. Cole, E. A. Novais, R. N. Louzada, and N. K. Waheed, "Contemporary retinal imaging techniques in diabetic retinopathy: A review, " Clinical & Experimental Ophthalmology, vol. 44, no. 4, pp. 289-299, 2016.
82. N. Takase, M. Nozaki, A. Kato, H. Ozeki, M. Yoshida, and Y. Ogura, "Enlargement of foveal avascular zone in diabetic eyes evaluated by en face optical coherence tomography angiography, " Retina, vol. 35, no. 11, pp. 2377-2383, 2015.
83. D. R. Matsunaga, J. J. Yi, L. O. De Koo, H. Ameri, C. A. Puliafito, and A. H. Kashani, "Optical coherence tomography angiography of diabetic retinopathy in human subjects, " Ophthalmic Surgery Lasers and Imaging Retina, vol. 46, no. 8, pp. 796-805, 2015.
84. P. D. Bradley, D. A. Sim, P. A. Keane et al., "The evaluation of diabetic macular ischemia using optical coherence tomography angiography, " Investigative Ophthalmology and Visual Science, vol. 57, no. 2, pp. 626-631, 2016.
85. T. S. Hwang, S. S. Gao, L. Liu et al., "Automated quantification of capillary nonperfusion using optical coherence tomography angiography in diabetic retinopathy, " JAMA Ophthalmology, vol. 134, no. 4, pp. 367-373, 2016.